Apollomics Class A Stock Price Patterns
| APLM Stock | 17.92 0.07 0.39% |
Momentum 54
Impartial
Oversold | Overbought |
Wall Street Target Price 2 | Quarterly Revenue Growth 2.623 |
Using Apollomics hype-based prediction, you can estimate the value of Apollomics Class A from the perspective of Apollomics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Apollomics to buy its stock at a price that has no basis in reality. In that case, they are not buying Apollomics because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Apollomics after-hype prediction price | USD 18.95 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Apollomics | Build AI portfolio with Apollomics Stock |
Apollomics After-Hype Price Density Analysis
As far as predicting the price of Apollomics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Apollomics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Apollomics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Apollomics Estimiated After-Hype Price Volatility
In the context of predicting Apollomics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Apollomics' historical news coverage. Apollomics' after-hype downside and upside margins for the prediction period are 10.96 and 26.94, respectively. We have considered Apollomics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Apollomics is risky at this time. Analysis and calculation of next after-hype price of Apollomics Class A is based on 3 months time horizon.
Apollomics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Apollomics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Apollomics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Apollomics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.69 | 7.99 | 1.03 | 0.02 | 3 Events / Month | 7 Events / Month | In about 3 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
17.92 | 18.95 | 5.75 |
|
Apollomics Hype Timeline
Apollomics Class A is presently traded for 17.92. The entity has historical hype elasticity of 1.03, and average elasticity to hype of competition of -0.02. Apollomics is expected to increase in value after the next headline, with the price projected to jump to 18.95 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is projected to be 5.75%, whereas the daily expected return is presently at 0.69%. The volatility of related hype on Apollomics is about 29592.59%, with the expected price after the next announcement by competition of 17.90. Apollomics generates negative cash flow from operationsGiven the investment horizon of 90 days the next expected press release will be in about 3 days. Check out Apollomics Basic Forecasting Models to cross-verify your projections.Apollomics Related Hype Analysis
Having access to credible news sources related to Apollomics' direct competition is more important than ever and may enhance your ability to predict Apollomics' future price movements. Getting to know how Apollomics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Apollomics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ICU | SeaStar Medical Holding | (0.05) | 8 per month | 0.00 | (0.19) | 9.58 | (9.88) | 34.66 | |
| MBRX | Moleculin Biotech | (0.50) | 9 per month | 0.00 | (0.20) | 9.37 | (11.73) | 41.63 | |
| ATHA | Athira Pharma | (0.54) | 8 per month | 3.40 | 0.11 | 7.83 | (6.40) | 70.38 | |
| LNAI | Lunai Bioworks | 0.05 | 8 per month | 0.00 | (0.01) | 12.62 | (8.82) | 55.92 | |
| THAR | Tharimmune | (0.18) | 9 per month | 4.77 | 0.11 | 11.15 | (9.23) | 35.56 | |
| BLRX | BioLineRx | (0.05) | 8 per month | 0.00 | (0.08) | 5.20 | (5.26) | 13.04 | |
| ADAP | Adaptimmune Therapeutics Plc | 0.03 | 22 per month | 15.04 | 0.03 | 22.82 | (18.18) | 168.52 | |
| LPTX | LPTX Old | 0.10 | 22 per month | 6.90 | 0.14 | 25.00 | (9.43) | 65.13 | |
| GOVX | GeoVax Labs | 0.65 | 9 per month | 0.00 | (0.28) | 9.38 | (13.70) | 42.89 | |
| ANL | Adlai Nortye Ltd | 0.22 | 6 per month | 5.83 | 0.17 | 15.22 | (11.76) | 42.22 |
Apollomics Additional Predictive Modules
Most predictive techniques to examine Apollomics price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Apollomics using various technical indicators. When you analyze Apollomics charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Apollomics Predictive Indicators
The successful prediction of Apollomics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Apollomics Class A, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Apollomics based on analysis of Apollomics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Apollomics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Apollomics's related companies. | 2023 | 2024 | 2025 | 2026 (projected) | Interest Debt Per Share | 6.47 | 1.24 | 1.42 | 1.35 | Revenue Per Share | 1.1 | 0.21 | 0.25 | 0.23 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Apollomics Basic Forecasting Models to cross-verify your projections. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Will Biotechnology sector continue expanding? Could Apollomics diversify its offerings? Factors like these will boost the valuation of Apollomics. If investors know Apollomics will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Apollomics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (52.80) | Revenue Per Share | Quarterly Revenue Growth 2.623 | Return On Assets | Return On Equity |
The market value of Apollomics Class A is measured differently than its book value, which is the value of Apollomics that is recorded on the company's balance sheet. Investors also form their own opinion of Apollomics' value that differs from its market value or its book value, called intrinsic value, which is Apollomics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Apollomics' market value can be influenced by many factors that don't directly affect Apollomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Apollomics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Apollomics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Apollomics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.